Literature
(research results)

Publications

  • Subbaian B, Yoshizue T, Wongnak R, Takemae H, Oba M, Mizutani T, Kuroda Y. An Escherichia coli Expressed Multi-Disulfide Bonded SARS-CoV-2 RBD Shows Native-like Biophysical Properties and Elicits Neutralizing Antisera in a Mouse Model. Int J Mol Sci. 2022 Dec 12;23(24):15744. (S3)
  • Yutaka Kuroda, Biophysical studies of amorphous protein aggregation and in vivo immunogenicity Biophysical Review, 23:1-7.2022.  (S1~S3)
  • Subbaian Brindha, Kuroda Yutaka*. A Multi-Disulfide Receptor-Binding Domain (RBD) of the SARS-CoV-2 Spike Protein Expressed in E. coli Using a SEP-Tag Produces Antisera Interacting with the Mammalian Cell Expressed Spike (S1) Protein. Int J Mol Sci. 2022 Feb 1;23(3):1703. doi: 10.3390/ijms23031703 (S2)
  • Rahman N, Miura S, Okawa M, Kibria MG, Islam MM, Kuroda Y. Solubility Controlling Peptide Tags of Opposite Charges Generate a Bivalent Immune Response Against Dengue ED3 Serotypes 3 and 4. Front Immunol. 2021 Jun 11;12:671590. doi: 10.3389/fimmu.2021.671590 (S3)
  • Kibria MG, Akazawa-Ogawa Y, Hagihara Y, Kuroda Y*. Immune response with long-term memory triggered by amorphous aggregates of misfolded anti-EGFR VHH-7D12 is directed against the native VHH-7D12 as well as the framework of the analogous VHH-9G8. European Journal of Pharmaceutics and Biopharmaceutics. 2021 Aug 165:13-21. doi: 10.1016/j.ejpb.2021.05.004.  (S2)
  • Rahman N, Islam MM, Kibria MG, Unzai S, Kuroda Y. A systematic mutational analysis identifies a 5-residue proline tag that enhances the in vivo immunogenicity of a non-immunogenic model protein. FEBS Open Bio. 2020 Oct;10(10):1947-1956. doi: 10.1002/2211-5463.12941. Rahman N, Islam MM, Unzai S, Miura S, Kuroda Y. Nanometer-Sized Aggregates Generated Using Short Solubility Controlling Peptide Tags Do Increase the In Vivo Immunogenicity of a Nonimmunogenic Protein. Mol Pharm. 2020 May 4;17(5):1629-1637. doi: 10.1021/acs.molpharmaceut.0c00071 (S2)
  • Islam MM, Miura S, Hasan MN, Rahman N, Kuroda Y*. Anti-Dengue ED3 Long-Term Immune Response With T-Cell Memory Generated Using Solubility Controlling Peptide Tags. Front Immunol. 2020 Mar 17;11:333. doi: 10.3389/fimmu.2020.00333. (S2)

List of patents

Patent No.6986261:Method for improving expression and yield of recombinant polypeptide
Patent No.5273438:Solubility calculation method for peptide-added biomolecules, and method for designing peptide tags and preventing inclusion body formation using the method
Patent No.7194442:Antigen composition